Retatrutide and Cardiovascular Risk Markers: Blood Pressure, Lipoproteins, ANGPTL3/8, Inflammation and the Missing Outcome Data

RESEARCH · RETATRUTIDE · CARDIOVASCULAR RISK MARKERS

Retatrutide and Cardiovascular Risk Markers: Blood Pressure, Lipoproteins, ANGPTL3/8, Inflammation and the Missing Outcome Data

PurixLab’s Retatrutide 10mg is a research vial of retatrutide, a single synthetic peptide that activates the GIP, GLP-1 and glucagon receptors. In the published trials the study material is the sponsor’s investigational compound, coded LY3437943, which is not the same thing as a research vial. Earlier articles in this series covered type 2 diabetes and the kidney, safety, tolerability and heart rate and the glucagon receptor and the liver. This overview turns to cardiovascular risk markers: blood pressure, lipoproteins, inflammatory proteins and metabolites, plus what the trials have not yet measured. These are findings from published studies, reported as the authors described them. The vial is supplied for laboratory research use only, and nothing here is guidance for human or veterinary use or a claim about any PurixLab product.

Where the data come from

Most of the detailed human cardiometabolic data come from two randomised, placebo-controlled phase 2 trials. One enrolled adults with obesity or overweight without diabetes for 48 weeks; the other enrolled adults with type 2 diabetes for 36 weeks and included a dulaglutide comparator [1]. The obesity trial enrolled 338 adults [2], and the diabetes trial randomly assigned 281 participants [3]. Both main reports focused on body weight and glycaemia. Most of the lipoprotein, inflammation and metabolite results discussed below therefore come from later post hoc analyses of stored fasting samples [1,4,5].

Blood pressure

Two meta-analyses of the randomised trials have pooled blood pressure. One estimated mean reductions of 6.79 mmHg in systolic and 2.46 mmHg in diastolic pressure with retatrutide compared with placebo [6]. An earlier meta-analysis of three trials with 878 patients reported larger mean differences of 9.88 mmHg systolic and 3.88 mmHg diastolic [7]. Pooled estimates shift with the trials included.

A broader meta-analysis of eighty-five randomised trials of incretin-based drugs in adults with overweight or obesity puts these numbers in context [8]. GLP-1 receptor agonists reduced systolic pressure by 3.4 mmHg, dual agonists by 5.1 mmHg and triple agonists by 6.6 mmHg, and greater weight loss was significantly associated with greater blood pressure reduction [8]. The authors call for long-term trials to clarify weight-independent mechanisms [8].

In the phase 3 TRIUMPH-2 trial in adults with obesity and type 2 diabetes, hypotension was reported in 14 participants (5%) in the 9 mg group and 18 (6%) in the 12 mg group, against one participant in the placebo group [9]. Heart rate tends to move the other way. In the phase 2 obesity trial, heart rate increases that rose with the assigned amount peaked at 24 weeks and declined thereafter [2].

Lipids and lipoprotein particles

The meta-analysis that pooled blood pressure also pooled standard lipids. It reported mean reductions in total cholesterol of 21.88 mg/dL, LDL cholesterol of 13.10 mg/dL and triglycerides of 40.90 mg/dL, with no significant effect on HDL cholesterol [6]. Heterogeneity for total cholesterol was high, with an I2 of 84%, so the size of that estimate is uncertain [6].

A more detailed post hoc analysis measured apolipoproteins and lipoprotein particle subclasses. In both phase 2 trials, retatrutide was associated with significant reductions in non-HDL cholesterol (up to 21.0% in the diabetes trial and 26.9% in the trial without diabetes) and apolipoprotein B (21.4% and 24.2%) [1]. The largest relative changes were in triglyceride-rich lipoproteins: large triglyceride-rich particles fell by 84.4% and 76.6%, and triglyceride-rich lipoprotein cholesterol by 29.4% and 38.6% [1]. Total and small LDL particles also fell, with small LDL particles reduced by 32.6% and 32.3% [1].

The glucagon question

Glucagon-receptor activity separates retatrutide from dual GIP and GLP-1 agonists, and its link with cholesterol has a history. Glucagon receptor blockers were developed to lower glucose in diabetes. With the small-molecule antagonist MK-0893, treatment was associated with rises in LDL cholesterol that grew with the amount given, and follow-up work linked the antagonist to increased cholesterol absorption rather than altered cholesterol synthesis [10]. A 12-week trial of the antagonist PF-06291874 in type 2 diabetes reported small increases in LDL cholesterol (less than 10%) and in blood pressure [11]. The antagonist antibody volagidemab, tested in type 1 diabetes, was associated with increases in serum transaminases, LDL cholesterol and blood pressure [12].

If blocking the receptor raises LDL cholesterol, activating it might be expected to lower it. A post hoc analysis of the retatrutide phase 2 trials examined one candidate pathway, the circulating angiopoietin-like protein 3/8 complex (ANGPTL3/8) [5]. ANGPTL3/8 concentrations fell in the 8 and 12 mg groups in type 2 diabetes and in the 1, 4, 8 and 12 mg groups in the trial without diabetes, and these decreases paralleled reductions in triglycerides and LDL cholesterol [5]. In primary human hepatocytes, both glucagon and retatrutide decreased ANGPTL3/8 secretion, and a glucagon-receptor antagonist antibody blocked the effect [5]. The authors suggest that this pathway could contribute to the lipid changes. A parallel change in a clinical trial does not prove cause, and weight loss itself lowers triglycerides.

Inflammation and the metabolome

Inflammatory markers gave a less consistent picture. High-sensitivity C-reactive protein fell by 54.8% and interleukin-6 by 29.6% in the trial without diabetes, but neither changed significantly in the diabetes trial [1].

A metabolomics and lipidomics analysis of fasting samples from 282 and 213 participants in the two trials found two clusters of change [4]. One involved markers of fatty acid oxidation, including 3-hydroxybutyrate, acetylcarnitine, free carnitine and long-chain acylcarnitines. The other involved metabolites associated with insulin resistance, including branched-chain amino acids and their breakdown products, urate and triglycerides with short-chain and saturated side chains. Mediation analyses suggested that changes in the first cluster accounted for 23.2% of the weight reduction in participants without diabetes and 12.7% in those with type 2 diabetes [4]. The authors’ favourable reading of these patterns is an interpretation of biomarkers, not an outcome.

What phase 3 has and has not reported

The phase 3 programme is larger and longer. TRIUMPH-1 randomised 2339 adults with obesity without diabetes for 80 weeks [13], and TRIUMPH-2 randomised 1152 adults with obesity and type 2 diabetes [9]. Their published abstracts concentrate on body weight, knee pain, sleep apnoea, glycaemia and adverse events rather than lipid or blood pressure end points.

No cardiovascular outcome results for retatrutide have been published. A 2026 review notes that phase 2 data for triple agonists produced large surrogate improvements, while phase 3 outcome data from the TRIUMPH programme remain awaited [14]. The same review cites mediation analyses of outcome trials of approved incretin drugs, which indicate that glycaemic improvement accounts for less than 15%-20% of the reduction in major adverse cardiovascular events [14]. Whether lower apolipoprotein B or blood pressure translates into fewer events with this specific molecule has not been tested.

What remains open

  • Post hoc, sponsor-run data. The lipoprotein, ANGPTL3/8 and metabolomic results are exploratory analyses of the phase 2 trials, largely by developer-affiliated authors [1,5,4].
  • Weight versus mechanism. Blood pressure falls track weight loss across incretin drugs, so weight-independent effects of glucagon-receptor activity are hard to isolate [8].
  • The glucagon paradox. Receptor antagonists raised LDL cholesterol in people, but evidence that agonism lowers it independently of weight loss is indirect and comes mainly from hepatocyte experiments [10,5].
  • Hypotension and heart rate. How lower blood pressure and higher heart rate balance out over years is unclear [9,2].
  • Hard outcomes. Cardiovascular event data are still awaited [14].

Retatrutide 10mg at PurixLab

Retatrutide 10mg: a labelled lyophilized research vial with 10mg per vial, C$119 per vial (CAD, before tax), supplied for laboratory research only. It is not the investigational trial material (LY3437943) described in the studies above. If your project needs particular supporting documentation, email [email protected] before ordering and tell us what you need. Product page: purixlab.com/product/retatrutide-10mg/.

PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.

In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge. There is no storefront or local pickup.

Payment is by Interac e-Transfer (instructions are shown at checkout). Current offers are shown on the product page and in your cart; offers do not stack.

For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.

View Retatrutide 10mg

Questions: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ

References

  1. Ruotolo G, Harris C, Lin Y, et al. Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes. Diabetes Obes Metab. 2026;28(11):10183-10194. PubMed 42608321 · PMC13646367 · doi:10.1111/dom.71200
  2. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PubMed 37366315 · doi:10.1056/NEJMoa2301972
  3. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. PubMed 37385280 · doi:10.1016/S0140-6736(23)01053-X
  4. Pearson MJ, Willency JA, Lin Y, et al. Retatrutide and lipid and metabolite profiles in participants with obesity with or without type 2 diabetes. J Clin Endocrinol Metab. 2026;111(11):3217-3228. PubMed 42135195 · PMC13671771 · doi:10.1210/clinem/dgag201
  5. Wen Y, Lemen D, Lin Y, et al. Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids. Diabetes Obes Metab. 2025;27(10):5985-5995. PubMed 40726454 · PMC12409240 · doi:10.1111/dom.16661
  6. Simental-Mendía LE, Barragán-Zúñiga LJ, Reyes-Avitia V. Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials. High Blood Press Cardiovasc Prev. 2026;33(5):503-516. PubMed 42371360 · doi:10.1007/s40292-026-00812-6
  7. Abdrabou Abouelmagd A, Abdelrehim AM, Bashir MN, et al. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. Proc (Bayl Univ Med Cent). 2025;38(3):291-303. PubMed 40291085 · PMC12026077 · doi:10.1080/08998280.2025.2456441
  8. Basile C, Merolla A, Mancusi C, et al. Effect of incretin-based therapies on blood pressure: a systematic review and meta-analysis. Eur J Prev Cardiol. 2026;33(7):1210-1217. PubMed 40899050 · doi:10.1093/eurjpc/zwaf560
  9. Bellido V, le Roux CW, Ekinci EI, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026;408(10563):1455-1472. PubMed 42810372 · doi:10.1016/S0140-6736(26)01861-1
  10. Guan HP, Yang X, Lu K, et al. Glucagon receptor antagonism induces increased cholesterol absorption. J Lipid Res. 2015;56(11):2183-2195. PubMed 26373568 · PMC4617405 · doi:10.1194/jlr.M060897
  11. Kazierad DJ, Chidsey K, Somayaji VR, et al. Efficacy and safety of the glucagon receptor antagonist PF-06291874: A 12-week, randomized, dose-response study in patients with type 2 diabetes mellitus on background metformin therapy. Diabetes Obes Metab. 2018;20(11):2608-2616. PubMed 29923286 · doi:10.1111/dom.13440
  12. Pettus J, Boeder SC, Christiansen MP, et al. Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial. Nat Med. 2022;28(10):2092-2099. PubMed 36192552 · PMC9872851 · doi:10.1038/s41591-022-02011-x
  13. Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. 2026;395(18):1781-1793. PubMed 42814954 · doi:10.1056/NEJMoa2604169
  14. Ravic M, Srejovic I, Milosavljevic I, et al. Cardiovascular effects of incretin receptor agonists: beyond glycemic control. Can J Physiol Pharmacol. 2026;104:1-13. PubMed 42721492 · doi:10.1139/cjpp-2026-0184

Leave a Comment

Your email address will not be published. Required fields are marked *